Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient

While attending The Liver Meeting® 2024, join us for best practices for applying advances in the diagnosis, treatment & management of MASLD/MASH.

Live Meeting

1.50 available credits

Information

November 17, 2024

12:30 PM - 02:00 PM PST

San Diego Convention Center
111 W Harbor Dr, Room: Ballroom 20A (Upper Level), San Diego, California, United States

Details

Presenters

Comments

Overview
MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists. 
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZ
Dr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.
Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.
Faculty:
Meena B. Bansal, MD, FAASLD
Professor of Medicine
System Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetic Group
Research: Histoindex, Pfizer, Siemens, The Kinetic Group
Mary E. Rinella, MD, FAASLD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, IL
Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
Take the appropriate action in a patient with risk factors for MASLD/MASH and a given risk stratification score
Demonstrate best practices for management of patients with MASLD
Select an appropriate treatment strategy for a patient with at-risk MASH 
Target Audience
This activity is designed to meet the educational needs of hepatologists, gastroenterologists, and advanced practice providers who work in hepatology practices, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with MASLD/MASH.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours. 

The Universal Activity Number for this program is JA0006235-0000-24-091-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net)
Provider(s)/Educational Partner(s)

Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Prova Education and supported by Madrigal Pharmaceuticals. This is not an official event/function of the American Association for the Study of Liver Diseases.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Naim Alkhouri, MD, FAASLD, DABOM

Meena B. Bansal, MD, FAASLD

Mary E. Rinella, MD, FAASLD

Details

Presenters

Comments

Overview
MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists. 
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZ
Dr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.
Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.
Faculty:
Meena B. Bansal, MD, FAASLD
Professor of Medicine
System Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetic Group
Research: Histoindex, Pfizer, Siemens, The Kinetic Group
Mary E. Rinella, MD, FAASLD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, IL
Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
Take the appropriate action in a patient with risk factors for MASLD/MASH and a given risk stratification score
Demonstrate best practices for management of patients with MASLD
Select an appropriate treatment strategy for a patient with at-risk MASH 
Target Audience
This activity is designed to meet the educational needs of hepatologists, gastroenterologists, and advanced practice providers who work in hepatology practices, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with MASLD/MASH.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours. 

The Universal Activity Number for this program is JA0006235-0000-24-091-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net)
Provider(s)/Educational Partner(s)

Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Prova Education and supported by Madrigal Pharmaceuticals. This is not an official event/function of the American Association for the Study of Liver Diseases.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Naim Alkhouri, MD, FAASLD, DABOM

Meena B. Bansal, MD, FAASLD

Mary E. Rinella, MD, FAASLD

Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
1.00 program credit
- Nicoletta Colombo, MD
1.00 program credit
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits

Recommended

Title

Share on ReachMD